[go: up one dir, main page]

AU2001272649A1 - Treatment of movement disorders - Google Patents

Treatment of movement disorders

Info

Publication number
AU2001272649A1
AU2001272649A1 AU2001272649A AU7264901A AU2001272649A1 AU 2001272649 A1 AU2001272649 A1 AU 2001272649A1 AU 2001272649 A AU2001272649 A AU 2001272649A AU 7264901 A AU7264901 A AU 7264901A AU 2001272649 A1 AU2001272649 A1 AU 2001272649A1
Authority
AU
Australia
Prior art keywords
treatment
movement disorders
disorders
movement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001272649A
Inventor
Jonathan Brotchie
Alan Crossman
Michael Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
Victoria University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria University of Manchester filed Critical Victoria University of Manchester
Publication of AU2001272649A1 publication Critical patent/AU2001272649A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001272649A 2000-07-22 2001-07-20 Treatment of movement disorders Abandoned AU2001272649A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0017951.5 2000-07-22
GBGB0017951.5A GB0017951D0 (en) 2000-07-22 2000-07-22 Treatment of movement disorders
PCT/GB2001/003260 WO2002007726A2 (en) 2000-07-22 2001-07-20 Treatment of movement disorders

Publications (1)

Publication Number Publication Date
AU2001272649A1 true AU2001272649A1 (en) 2002-02-05

Family

ID=9896102

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001272649A Abandoned AU2001272649A1 (en) 2000-07-22 2001-07-20 Treatment of movement disorders

Country Status (3)

Country Link
AU (1) AU2001272649A1 (en)
GB (1) GB0017951D0 (en)
WO (1) WO2002007726A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800891D0 (en) * 1988-01-15 1988-02-17 Lilly Industries Ltd Pharmaceutical compounds
US5427942A (en) * 1991-11-13 1995-06-27 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Human D5 dopamine recepltor gene and uses
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid

Also Published As

Publication number Publication date
GB0017951D0 (en) 2000-09-13
WO2002007726A8 (en) 2002-05-02
WO2002007726A3 (en) 2002-09-06
WO2002007726A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
AU4256801A (en) Treatment of movement disorders
AU2002223827A1 (en) Well treatment
AU2002257936A1 (en) Methods of well treatment
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2002231206A1 (en) Treatment of depression
AU2002360555A1 (en) Treatment of genitourinary tract disorders
AUPR074500A0 (en) Treatment of t cell disorders
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
AU2001239510A1 (en) Treatment of renal disorders
AU2002319286A1 (en) Skin treatment
AU7106300A (en) Treatment of skin disorders
AU2002228652A1 (en) Treatment of disorders using polyethylenimine diazeniumdiolate
AUPR610501A0 (en) Treatment of parasitic disease
AU3899100A (en) Treatment of hyperactivity disorders
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU2080201A (en) Treatment of addiction disorders
AU2001261324A1 (en) Psoriasis treatment
AU2001272649A1 (en) Treatment of movement disorders
AU2001253560A1 (en) Methods of treatment
AU2001274446A1 (en) Vip-related peptides for the treatment of skin disorders
AU3582101A (en) The treatment of functional gastrointestinal disorders
AU2002242293A1 (en) Treatment of neurological disease
HK1063438A (en) Treatment of anxiety disorders